Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Dabogratinib · TYRA-300

Small molecule · Inhibitor of fibroblast growth factor receptor 3 (FGFR3) · developed by Tyra Biosciences

Phase 2 Most advanced trial
TYRA Developer
5 Registered trials

What is Dabogratinib?

Dabogratinib (TYRA-300) is an orally bioavailable, selective inhibitor of fibroblast growth factor receptor 3 (FGFR3), a receptor tyrosine kinase. It binds FGFR3 activating alterations, including the V555L/M gatekeeper mutants, to block FGFR3-mediated signaling. It is being studied in urothelial carcinoma and other solid tumors with FGFR3 alterations.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
TYRA-300
Drug type
Small molecule
Targets
fibroblast growth factor receptor 3 (FGFR3)
Mechanism
Inhibitor of fibroblast growth factor receptor 3 (FGFR3)
Pathways
angiogenesis, tumor cell proliferation, FGFR3-mediated signaling
Therapy area
Oncology
Developer
Tyra Biosciences, Inc (TYRA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
FH245S2JZJ

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07265947 Phase 2 Low Grade Upper Tract Urothelial Carcinoma Recruiting TYRA
NCT06995677 Phase 2 Low-grade NMIBC Recruiting TYRA
NCT06842355 Phase 2 Achondroplasia Recruiting TYRA
NCT05544552 Phase 1/2 Locally Advanced Urothelial Carcinoma Active not recruiting TYRA
NCT06006702 Phase 1 Healthy Active not recruiting TYRA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid TumorAdvanced Urothelial CarcinomaBladder CancerFGFR3 Gene AlterationFGFR3 Gene MutationHealthyLocally Advanced Urothelial CarcinomaMetastatic Urothelial CarcinomaNon-muscle-invasive Bladder CancerSolid TumorSolid Tumor, AdultUrinary Tract CancerUrinary Tract CarcinomaUrinary Tract Tumor

Other drugs acting on FGFR3

More from Tyra Biosciences

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the TYRA page.

Follow TYRA, the company behind Dabogratinib

See TYRA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TYRA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.